Three new general devices were classified as class II with special controls by the US Food and Drug Administration, all effective 16 August.
Two general classifications came about from de novo devices made by BioFire Diagnostics Inc.. On 20 November 2020, Biofire...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?